What insurance policy changes affect New Mexico providers?

This page tracks changes from major payers (including Medicaid managed care, commercial insurers, and Medicare Advantage plans) that explicitly apply to New Mexico. Changes include prior authorization updates, billing code additions or deletions, and reimbursement rate revisions.

How often are New Mexico policy changes updated?

Our scrapers run daily and publish new findings within 24 hours of detection. Each change includes an effective date where stated so you can prioritize what requires immediate action.

How do I get alerted to new New Mexico insurance policy changes?

Create a free alert on PolicyChanges.app and filter by state to New Mexico. You will get an email when new matching changes are detected: daily or weekly, your choice, on every plan.

PAYER POLICY CHANGES

New Mexico Insurance & Medicaid Policy Updates

New Mexico providers face a continuous stream of payer policy changes: coverage edits, prior authorization expansions, billing code revisions, and Medicaid reimbursement updates that affect day-to-day practice operations. This page surfaces every tracked policy change that explicitly names New Mexico, so your billing and compliance teams can act before the effective date, not after a claim denial.

UnitedHealthcare · Effective Dec 1, 2026High impact
Cardiovascular Disease Risk Tests (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico (Medicaid) is revising its cardiovascular disease risk testing policy effective December 1, 2026. The policy narrows coverage by removing lipoprotein(a) testing from the unproven list (making it potentially coverable) while adding noninvasive point-of-care cardiac platforms like CorVista System to the non-covered list, and updating applicable CPT codes with a new quarterly edit code (1104T) and removal of code 83695.
BCBS New Mexico · Effective Dec 1, 2026High impact
New Claims Editing Rules To Be Implemented in December 2026
Effective December 1, 2026, Blue Cross Blue Shield of New Mexico will implement new claims editing rules in the Lyric software database that add maximum unit limits and frequency restrictions for five specific drug codes (J0897, J0178, J2778, J2502, Q5128) and enforce proper application of drug wastage modifiers (JW/JZ) on single-use vial claims. Claims that fail these edits will receive denial reason codes beginning with the letter 'G'.
BCBS New Mexico · Effective Dec 21, 2026High impact
Prior Authorization Changes for Some Government Program Members
Blue Cross Blue Shield of New Mexico is removing prior authorization requirements for specific service categories (proprietary laboratory analyses, drugs/biologics, molecular pathology, infectious disease testing, radiology, advanced imaging, orthopedic surgery, foot and ankle surgery, plastic/reconstructive surgery, vascular surgery, organ transplant, general surgery, and ophthalmology) for Medicare Advantage members effective December 21, 2026. Additionally, the plan will begin phasing out the 'Recommended Clinical Review' option starting January 1, 2027, with full removal expected by end of 2027 for most commercial members.
UnitedHealthcare · Effective Jan 1, 2027High impact
Denosumab
Effective 2027-01-01, UnitedHealthcare Community Plan of New Mexico Medicaid expanded its denosumab policy: Jubereq and Osvyrti are preferred products covered under the Diagnosis-Specific Criteria, while Boncresa, Oziltus, and Ponlimsi are non-preferred and covered only when the Preferred Product Criteria and Diagnosis-Specific Criteria are both met. The postmenopausal osteoporosis criteria add a very-high-fracture-risk pathway for initial therapy, and HCPCS codes Q5166, Q5171, and Q5173 were added.
UnitedHealthcare · Effective Jan 1, 2027High impact
New oncology prior authorization code updates
Effective January 1, 2027, UnitedHealthcare is adding prior authorization requirements for 11 HCPCS oncology medication codes when administered in outpatient settings for cancer treatment. These codes include busulfan, leucovorin calcium, luspatercept, dexrazoxane, dinutuximab, octreotide, triptorelin, omidubicel, zoledronic acid, and cyclosporine. This change applies across commercial, Medicare Advantage, Medicaid, and Individual Exchange plans.
BCBS New Mexico · Effective Jan 1, 2027High impact
New Digital Interfaces To Simplify Prior Authorization Requests
Effective January 1, 2027, Blue Cross Blue Shield of New Mexico will launch secure application programming interfaces (APIs) to streamline prior authorization requests. These digital interfaces will allow providers to determine prior authorization requirements, access patient data (prior auth status, encounter data, claims data) through their EHR systems, submit and update requests, and track status in real time. This applies to Medicare Advantage, Medicaid, and select commercial members.
BCBS New Mexico · Effective Jan 1, 2027High impact
Watch for New Edge Benefit Plan Members in 2027
Beginning January 1, 2027, Blue Cross and Blue Shield of New Mexico will introduce new Edge benefit plans powered by Easify℠, which are copay-only PPO plans with tiered copay options based on provider network tier. Billing teams must verify member ID cards, confirm correct copay amounts via Availity Essentials before appointments, and include the rendering provider's NPI on all claims. Edge members have no coinsurance or deductibles for in-network covered services.
BCBS New Mexico · Effective Jan 1, 2027High impact
We’ll Begin Removing Recommended Clinical Review as an Optional Medical Necessity Review, Effective Jan. 1, 2027
Blue Cross Blue Shield of New Mexico will eliminate 'recommended clinical review' as an optional medical necessity review option for commercial members, effective January 1, 2027. Services that previously used recommended clinical review may now require prior authorization instead. Billing teams must verify eligibility and prior authorization requirements through Availity Essentials before rendering services.
UnitedHealthcare · Effective Dec 1, 2026Medium impact
Omalizumab
Effective 2026-12-01, UnitedHealthcare Community Plan of New Mexico Medicaid revised its omalizumab medical policy: the title changed from Xolair to Omalizumab, the policy now covers Omlyclo (omalizumab-igec), Xolair, and any FDA-approved and launched omalizumab biosimilar (biosimilars not named are non-preferred until reviewed by UnitedHealthcare), HCPCS code Q5154 was added, and self-administered omalizumab is obtained under the pharmacy benefit rather than the medical benefit. Billing teams should update charge entry and product references so omalizumab claims for these members use the correct benefit and product codes.
UnitedHealthcare · Effective Dec 1, 2026Medium impact
Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
UnitedHealthcare Community Plan of New Mexico revised its Medicaid medical policy for amyloid-directed monoclonal antibodies (Leqembi and Kisunla) for Alzheimer's disease, effective 2026-12-01. Continuation-of-therapy criteria now require an Alzheimer's diagnosis and MRI monitoring for ARIA per FDA labeling, drop the earlier requirement for documented follow-up brain MRI, and add dosing-regimen criteria for intravenous Leqembi 10 mg/kg every two weeks. Leqembi IQLIK subcutaneous self-injection is handled under the pharmacy benefit unless the member's benefit plan says otherwise.
UnitedHealthcare · Effective Dec 1, 2026Medium impact
Maximum Dosage and Frequency
UnitedHealthcare Community Plan of New Mexico revised its Maximum Dosage and Frequency medical policy, updating the list of maximum allowed quantities and frequencies by HCPCS units, adding Exdensur (depemokimab) and Spinraza (nusinersen), adding HCPCS codes J2326 and J2361, and revising the descriptions of Q5136 and Q5157. Billing teams should check claim quantities and units for these drugs against the new limits before submitting claims for dates of service on or after the effective date.
UnitedHealthcare · Effective Dec 1, 2026Medium impact
Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)
UnitedHealthcare Community Plan of New Mexico added Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for glycogen storage disease type Ia, to its Medicaid medical benefit drug policy as a new policy effective 2026-12-01. Coverage is limited to patients aged 8 or older with confirmed diagnosis (G6PC bi-allelic variants or absent G6Pase activity on liver biopsy), current cornstarch therapy, no detectable AAV8 antibodies, no prior gene therapy, specialist prescribing, no planned inpatient admission solely for administration, FDA-labeled dosing, and authorization for one lifetime treatment lasting no more than 45 days from approval.
UnitedHealthcare · Effective Dec 1, 2026Medium impact
Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico revised its coverage policy for TARE/SIRT (yttrium-90 microspheres) for liver cancer treatment, effective December 1, 2026. The key change replaced "metastasis from uveal/ocular melanoma" with "metastasis from uveal melanoma" in the list of covered indications. The policy also updated definitions and clinical evidence sections. Coverage applies to patients 19+ years with ECOG Performance Status 0-2; patients under 19 are automatically covered without prior review.
UnitedHealthcare · Effective Dec 1, 2026Medium impact
Breast Imaging for Screening and Diagnosing Cancer (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico (Medicaid) revised its breast imaging policy effective December 1, 2026, narrowing coverage for molecular breast imaging by explicitly excluding routine screening use and clarifying that Positron Emission Mammography is not covered. The policy also refined terminology for MRI elastography and updated clinical evidence. Billing teams must ensure claims for excluded modalities are not submitted for routine screening cases, even in high-risk patients.
BCBS New Mexico · Effective Dec 11, 2026Medium impact
Watch for Digital Access to Medicare Advantage Prior Authorization Decision Letters via Availity® Essentials
Blue Cross Blue Shield of New Mexico is transitioning Medicare Advantage prior authorization approval letters from U.S. Postal Service mail to digital-only delivery via Availity Essentials Provider Correspondence Viewer, effective December 11, 2026. Beginning October 8, 2026, providers can access these letters digitally; denial letters will continue to be mailed and also available digitally. An opt-out option for mail delivery will be provided in future communications.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
Saphnelo® (Anifrolumab-Fnia)
UnitedHealthcare Community Plan of New Mexico revised its Saphnelo (anifrolumab-fnia) IV medical policy, effective 2027-01-01. Coverage for moderate to severe SLE now requires a prescriber attestation, with an explanation, that the patient or caregiver cannot be trained or is physically unable to self-administer Saphnelo or Benlysta, plus a history of failure, contraindication, or intolerance to Benlysta IV or SQ. Continuation and initial authorizations are limited to 12 months, and use with biologics or in severe active CNS lupus or severe active lupus nephritis remains not covered.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
FcRn Blockers
Effective 2027-01-01, UnitedHealthcare Community Plan of New Mexico (Medicaid) revised its FcRn Blockers medical benefit drug policy to state that Imaavy (nipocalimab-aahu) is proven and medically necessary for warm autoimmune hemolytic anemia (wAIHA) in adults and children 12 and older who currently or previously received corticosteroids, with added ICD-10 code D59.11. Billing teams should align prior authorization requests, documentation and charge entry for Imaavy and the other listed FcRn blocker products (Rystiggo, Vyvgart, Vyvgart Hytrulo IV/SC vial) with the revised criteria.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico revised its Medicaid medical policy for Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions), effective 2027-01-01. Pretest genetic counseling is now described as recommended rather than strongly recommended, the test-ordering criterion now allows orders placed in consultation with a listed specialist, the policy's outpatient or discharge-only scope is reworded, and CPT codes 0670U through 0677U were added to the applicable codes list.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for New Mexico Only)
Effective 2027-01-01, UnitedHealthcare Community Plan of New Mexico Medicaid members' occipital nerve injection and ablation coverage policy adds CPT codes 1057T, 1058T, 1059T, 1060T, and 1061T and removes CPT code 64570. Billing teams should update charge entry and claim edits for these codes for New Mexico Medicaid members starting 2027-01-01.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico revised its Molecular Oncology Testing for Hematologic Cancer policy, effective 2027-01-01, for New Mexico Medicaid members. Multigene panels of up to 50 genes are covered when performed at initial diagnosis or relapse, ordered by a hematologist or oncologist, and intended for listed conditions; clonoSEQ is covered for clonality and measurable residual disease testing, and several other molecular oncology tests (including EpiSwitch Checkpoint Inhibitor Response Test, optical genome mapping and whole-transcriptome sequencing) are deemed unproven. Billing teams should confirm test ordering, diagnosis documentation, and CPT coding on molecular oncology claims for these members before the effective date. By 2027-01-01: Billing team should update charge entry and claim edits for molecular oncology orders so that claims for CPT codes 0332U, 0592U, 0644U and 0645U, and removed codes 0485U, 0560U and 0561U, are coded to the revised criteria, and ensure ordering provider specialty (hematology or oncology) and the diagnosis and treatment-stage documentation are captured on the requisition for New Mexico Medicaid members. Providers and front desk staff should be told that unproven tests listed in the policy are not covered for these members and that orders for those tests should be reviewed before collection.
UnitedHealthcare · Effective Jan 1, 2027Medium impact
Bariatric Surgery (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico's November 2026 bulletin updated the Bariatric Surgery medical policy for New Mexico Medicaid members, effective 2027-01-01. The update removed CPT code 43882 from the applicable codes list and removed the Medical Records Documentation Used for Reviews section, which now points to UHCprovider.com for that information.
BCBS New Mexico · Effective Jan 1, 2027Medium impact
Changes Coming to the Medical Drug Benefit Program
Effective January 1, 2027, Blue Cross and Blue Shield of New Mexico is expanding its Medical Drug Benefit Program to update coverage for prescription drugs administered by healthcare providers in clinical settings. The program now defines coverage for therapeutic alternatives, new-to-market drugs, FDA-accelerated approval drugs, and drugs with limited medical benefit coverage. This change applies only to commercial members and does not affect Medicaid, HMO, Federal Employee Program, or Postal Employee Program members.
BCBS New Mexico · Effective Jan 1, 2027Medium impact
Updates to Behavioral Health Substance Abuse Criteria for Utilization Management
Blue Cross Blue Shield of New Mexico is expanding its use of ASAM (American Society of Addiction Medicine) Criteria 4.0 for utilization management and medical necessity reviews. Effective January 1, 2027, ASAM Criteria 4.0 will be applied to adolescent behavioral health and substance abuse services in addition to adult services already using this standard.
BCBS New Mexico · Effective Feb 1, 2027Medium impact
Enhanced Review of Laboratory, Genetic and Molecular Testing Claims
Effective February 1, 2027, Blue Cross and Blue Shield of New Mexico will implement enhanced claims review for laboratory, genetic, and molecular testing services using AMA and CMS National Correct Coding Initiative guidelines. Claims for dates of service on or after February 1, 2027, will be reviewed by Concert (a contracted healthcare technology company) for proper coding compliance; denied claims will receive notification with next steps.
UnitedHealthcare · Effective Dec 1, 2026Low impact
Pasatru™ (Garetosmab-Grts)
UnitedHealthcare Community Plan of New Mexico added a medical policy for Pasatru (garetosmab-grts) for fibrodysplasia ossificans progressiva (FOP) in Medicaid members, effective 2026-12-01. Initial therapy requires patients over 18, an FOP diagnosis, chart notes and genetic testing confirming an ACVR1 mutation, prescribing by or with an FOP expert, dosing per FDA labeling, no combination with Sohonos, and authorization for no more than 12 months; continuation requires documented positive response and reauthorization for no more than 12 months.
UnitedHealthcare · Effective Dec 1, 2026Low impact
Ilaris® (Canakinumab)
UnitedHealthcare Community Plan of New Mexico's November 2026 Medicaid medical policy update revises the Ilaris (canakinumab) coverage rationale for Active Still's Disease, including adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA), to state that members must not be receiving Ilaris in combination with another systemic targeted immunomodulator for the same indication. Billing staff should confirm that claims for these members reflect whether a concurrent systemic targeted immunomodulator is being given for the same indication.
UnitedHealthcare · Effective Nov 1, 2026High impact
Evenity ® (Romosozumab-Aqqg)
UnitedHealthcare Community Plan of New Mexico revised coverage criteria for Evenity® (Romosozumab-Aqqg), expanding eligibility to include patients with very high fracture risk (recent fracture in past 12 months, fracture on osteoporosis therapy, multiple fractures, fractures on skeletal-harming drugs, BMD T-score <-3.0, high fall risk, or FRAX 10-year probabilities ≥30% major osteoporotic fracture or ≥4.5% hip fracture). Coverage remains limited to 12 months with specified exclusions for combination therapy and requires prior authorization.
UnitedHealthcare · Effective Nov 1, 2026High impact
Medicaid: Paper submissions no longer accepted
Effective November 1, 2026, UnitedHealthcare Community Plan (Medicaid) in Hawaii, New Mexico, Rhode Island, and Wisconsin will no longer accept paper submissions for post-service appeals. All appeals must be submitted electronically via the UnitedHealthcare Provider Portal or API. Paper appeals will not be reviewed.
UnitedHealthcare · Effective Nov 1, 2026High impact
Medicaid: Prior auth reduction efforts expand to more states
UnitedHealthcare Community Plans is expanding prior authorization reductions across six states, eliminating prior auth requirements for select CPT codes effective November 1, 2026 (Arizona, New Mexico, New York, Ohio) and December 1, 2026 (Missouri, Washington). Billing teams must identify which codes are impacted in their state and remove prior authorization requirements from workflows for affected procedures.
UnitedHealthcare · Effective Nov 1, 2026High impact
Spinal Fusion and Decompression (for New Mexico Only)
UnitedHealthcare Community Plan of New Mexico revised its Spinal Fusion and Decompression policy for Medicaid beneficiaries, effective November 1, 2026. Key changes include: (1) updated clinical coverage criteria to reference a new InterQual® Client Defined custom lumbar decompression/fusion guideline, (2) added six new clinical definitions (Anticipated Instability Due to Procedure, Instability, Lumbar Spinal Decompression With Interbody Lumbar Spinal Fusion, Meyerding Classification System, Radiographic Dynamic Instability, and Unstable Grade I Degenerative Spondylolisthesis), and (3) clarified that staged multiple sessions for symptomatic multisite spinal pathology are unproven and not medically necessary when one session can address all sites. Four procedures remain unproven and non-covered: Dynamic Stabilization systems, Facet Joint Replacement, Isolated Facet Joint Fusion (with or without instrumentation), and Vertebral joint implants (e.g., MOTUS).
Humana · Effective Oct 1, 2026High impact
Molecular Biomarkers for Prostate Cancer Risk Stratification - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage coverage policy for molecular biomarker tests used in prostate cancer risk stratification (effective 10/1/2026). The policy establishes coverage criteria for tests like ArteraAI, EpiSwitch, IsoPSA, MyProstateScore 2.0, ProMark, and ProsTAV, with coverage determinations based on MAC-specific LCDs/LCAs that vary by geographic jurisdiction. Billing teams must identify the correct MAC jurisdiction and apply the corresponding LCD requirements for each test ordered.
BCBS New Mexico · Effective Oct 1, 2026High impact
Prior Authorization Changes for Some Commercial and Government Program Members
Blue Cross Blue Shield of New Mexico is restructuring prior authorization and clinical review processes across commercial and government plans, effective in two phases: October 1, 2026 (commercial medical oncology drugs) and January 1, 2027 (genetic testing, sleep services, oncology, orthotics, wound care, and DME codes). Multiple utilization management vendors (Carelon, Evicore, Alacura) will handle different service categories. Additionally, 'recommended clinical review' will be phased out entirely by end of 2027 for most commercial members.
Humana · Effective Oct 1, 2026High impact
Bariatric Surgery - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage bariatric surgery coverage policy (HUM-1020-005) effective October 1, 2026, that outlines coverage determinations, limitations, and coding requirements for various bariatric procedures. The policy applies Humana's Medicare Advantage coverage standards and references applicable MAC Local Coverage Determinations by geographic jurisdiction, with specific rules varying by state and MAC region.
New Mexico Medicaid · Effective Oct 1, 2026High impact
Supplement 26-06: State of New Mexico Handicapping Labio-lingual Deviation (NM HLD) Index Report Form – MAD 908
New Mexico Medicaid requires providers to submit prior authorization requests for comprehensive orthodontic treatment using the standardized MAD 908 form (HLD Index Report Form) beginning October 1, 2026. Requests submitted without this form will be rejected and must be resubmitted, potentially resulting in claim denials.
BCBS New Mexico · Effective Oct 1, 2026High impact
Prior Authorization Changes for Some Commercial and Government Program Members
Blue Cross Blue Shield of New Mexico is restructuring prior authorization requirements for commercial and government program members, removing prior auth requirements for certain code categories (behavioral health, miscellaneous, oncology, immunology/specialty infusion, laboratory/molecular diagnostics) while adding new code categories (radiation oncology, emerging technology) to be reviewed by different utilization management vendors. Changes take effect on two dates: October 1, 2026 and January 1, 2027.
UnitedHealthcare · Effective Oct 1, 2026High impact
New Mexico Medicaid: Requirement to enroll with state delayed to October
New Mexico Medicaid has extended the provider enrollment deadline from July 1, 2026 to October 1, 2026. All attending, referring, ordering, and prescribing providers and pharmacists must enroll with the state by this date or have claims denied for services rendered on or after October 1, 2026. Providers must include NPI, TIN, and Payer ID 87748 (87726 for electronic visit verification) on claims.
BCBS New Mexico · Effective Sep 18, 2026High impact
Learn About Enhancements to Medicaid Utilization Management Process, Effective Sept. 18, 2026
Blue Cross Blue Shield of New Mexico is launching Medicaid Authorizations, a new real-time prior authorization submission and management tool within Availity Essentials effective September 18, 2026. This replaces manual processes and allows providers to check authorization requirements, submit requests, upload documentation, and track status 24/7 through a streamlined digital workflow.
Humana · Effective Sep 1, 2026High impact
Spinal Fusion Surgery - Medicare Advantage (Revised)
This is a revised Medicare Advantage medical coverage policy for spinal fusion surgery (effective 09/01/2026) that consolidates coverage determination, limitations, coding information, and evidence summaries for cervical, lumbar, and thoracic spinal fusion procedures. The policy references multiple MAC-specific Local Coverage Determinations (LCDs) across geographic jurisdictions and outlines covered procedures including traditional fusion, minimally invasive approaches (DLIF, XLIF, MITLIF), sacroiliac joint fusion, and interlaminar fusion techniques. Billing teams must align claims submission with the applicable MAC LCD based on patient location and ensure procedures meet specific medical necessity criteria outlined in the referenced determinations.
Humana · Effective Sep 1, 2026High impact
Benign Prostatic Hyperplasia Treatments - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage coverage policy for Benign Prostatic Hyperplasia treatments effective September 1, 2026. The policy outlines coverage determinations for multiple BPH treatment modalities including surgical procedures (TURP, prostatectomy, laser therapies), temporary implanted devices, stents, and diagnostic testing. The policy references multiple MAC-specific Local Coverage Determinations (LCDs) that vary by geographic jurisdiction, requiring billing teams to verify applicable coverage rules based on patient location.
Humana · Effective Sep 1, 2026High impact
Ambulatory Cardiac Monitoring Devices - Medicare Advantage (Revised)
Humana Medicare Advantage has revised its Ambulatory Cardiac Monitoring Devices policy effective September 1, 2026. The policy provides updated coverage guidance for various cardiac monitoring technologies (Holter monitors, patch recorders, external loop monitors, implantable loop recorders, and mobile cardiac outpatient telemetry) with MAC-specific coverage determinations by geographic jurisdiction. The policy document appears incomplete but establishes that medical necessity determinations will follow applicable NCDs and LCDs based on the member's jurisdiction.
Humana · Effective Aug 6, 2026High impact
Neuroablative Techniques for Chronic Pain - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage coverage policy for neuroablative techniques used to treat chronic pain, effective 08/06/2026. The policy defines coverage criteria, eligible procedures (including radiofrequency ablation, cryoablation, chemical neurolysis, and specialized devices like Intracept), and references MAC-specific LCDs and billing codes by geographic jurisdiction. Billing teams must verify applicable MAC guidelines for their state and ensure claims comply with local coverage determinations.
Humana · Effective Aug 6, 2026High impact
Neuroablative Techniques for Chronic Pain - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage policy on neuroablative techniques for chronic pain management, effective 08/06/2026. The policy defines covered denervation procedures (radiofrequency ablation, cryoablation, facet denervation, basivertebral nerve ablation, and others) and references MAC-specific LCDs and NCDs that vary by geographic jurisdiction. Billing teams must verify applicable MAC requirements for their region before processing claims for these procedures.
Humana · Effective Aug 3, 2026High impact
Genetic Testing for Hereditary Cancer - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage policy on genetic testing for hereditary cancer syndromes, effective August 3, 2026. The policy establishes coverage guidelines for germline genetic testing across multiple cancer types (melanoma, gastric cancer, neuroendocrine tumors, renal cell carcinoma, and others) and references specific MAC-based Local Coverage Determinations (LCDs) that vary by geographic jurisdiction. Billing teams must verify applicable MAC jurisdiction and LCD requirements before processing claims.
Humana · Effective Aug 3, 2026High impact
Breast Reconstruction - Medicare Advantage (Revised)
Humana Medicare Advantage has revised its breast reconstruction coverage policy (effective 08/03/2026) to clarify medical necessity criteria for reconstruction procedures following mastectomy, trauma, or congenital abnormalities. The policy applies MAC-specific Local Coverage Determinations (LCDs) by geographic jurisdiction and establishes criteria for determining coverage of implant removal, reduction mammaplasty, and related procedures. Billing teams must identify the appropriate MAC jurisdiction for each claim and apply the correct LCD requirements.
Humana · Effective Aug 3, 2026High impact
Breast Excision and Mastectomy - Medicare Advantage (Revised)
Humana Medicare Advantage has updated its Breast Excision and Mastectomy policy (HUM-1254-009) effective 08/03/2026. This revised policy clarifies coverage criteria for breast lesion excisions (CPT 19120, 19125), partial mastectomies (CPT 19301, 19302), and gynecomastia mastectomy (CPT 19300) across multiple MAC jurisdictions. The policy establishes specific medical necessity criteria based on biopsy results, lesion characteristics, and anatomical considerations, and applies jurisdiction-specific Local Coverage Determinations (LCDs) for Medicare Administrative Contractors.
Humana · Effective Aug 3, 2026High impact
Benign Prostatic Hyperplasia Treatments - Medicare Advantage (Revised)
This is a comprehensive Medicare Advantage policy for Benign Prostatic Hyperplasia (BPH) treatments that became effective on August 3, 2026. The policy outlines coverage for multiple surgical and minimally invasive treatment modalities including TURP, laser therapies, temporary implanted devices, and stents, with specific coverage determinations varying by MAC jurisdiction. Billing teams must verify applicable MAC-specific LCDs and NCDs by geographic location before processing BPH treatment claims.
BCBS New Mexico · Effective Aug 1, 2026High impact
Prior Authorization Changes for Some Commercial and Government Program Members
Blue Cross Blue Shield of New Mexico is implementing significant prior authorization requirement changes across multiple service categories (radiology advanced imaging, sleep services, molecular genetic testing, medical oncology, and miscellaneous drug codes) effective October 1, 2026 for commercial and Medicaid Turquoise Care members, and August 1, 2026 for Medicare Advantage members. These changes involve shifting utilization management review responsibilities between BCBSNM, Carelon, and Evicore, and require billing teams to verify current prior authorization requirements before rendering services.
BCBS New Mexico · Effective Jul 15, 2026High impact
New Claims Editing Rules To Be Implemented in July 2026
Blue Cross Blue Shield of New Mexico is implementing comprehensive claims editing rules in July 2026 that will automatically deny or rebundle claims with coding errors, affecting radiation therapy, STI testing, colonoscopies, hospital services, and many other procedures. Claims receiving edits will show ineligible reason codes starting with 'G'.
BCBS New Mexico · Effective Jul 8, 2026High impact
Two New Claims Editing Rules To Be Implemented in July 2026
Blue Cross Blue Shield of New Mexico will implement two new claims editing rules in July 2026: a Laterality Diagnosis Check that will deny claims with inconsistent modifiers (LT/RT/50) and diagnoses, and a Revenue Code and Procedure rule that validates HCPCS codes with implant revenue codes 275, 276, and 278. Claims receiving these edits will show ineligible reason codes with an alpha character 'G'.
BCBS New Mexico · Effective Jul 1, 2026High impact
Claim Editing Changes for Evaluation and Management Services for Commercial and Turquoise Care Members, Effective July 1, 2026
Effective July 1, 2026, Blue Cross Blue Shield of New Mexico will implement enhanced claims editing for evaluation and management services that may automatically downcode E&M claims to lower service levels if documentation doesn't support the billed level. Providers can appeal by submitting medical records if they disagree with the downcoded reimbursement level.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Cardiovascular Disease Risk Tests (for New Mexico Only)

New Claims Editing Rules To Be Implemented in December 2026

Prior Authorization Changes for Some Government Program Members

Denosumab

New oncology prior authorization code updates

New Digital Interfaces To Simplify Prior Authorization Requests

Watch for New Edge Benefit Plan Members in 2027

We’ll Begin Removing Recommended Clinical Review as an Optional Medical Necessity Review, Effective Jan. 1, 2027

Omalizumab

Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease

Maximum Dosage and Frequency

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)

Transarterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver (for New Mexico Only)

Breast Imaging for Screening and Diagnosing Cancer (for New Mexico Only)

Watch for Digital Access to Medicare Advantage Prior Authorization Decision Letters via Availity® Essentials

Saphnelo® (Anifrolumab-Fnia)

FcRn Blockers

Whole Exome and Whole Genome Sequencing (Non-Oncology Conditions) (for New Mexico Only)

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for New Mexico Only)

Molecular Oncology Testing for Hematologic Cancer Diagnosis, Prognosis, and Treatment Decisions (for New Mexico Only)

Bariatric Surgery (for New Mexico Only)

Changes Coming to the Medical Drug Benefit Program

Updates to Behavioral Health Substance Abuse Criteria for Utilization Management

Enhanced Review of Laboratory, Genetic and Molecular Testing Claims

Pasatru™ (Garetosmab-Grts)

Ilaris® (Canakinumab)

Evenity ® (Romosozumab-Aqqg)

Medicaid: Paper submissions no longer accepted

Medicaid: Prior auth reduction efforts expand to more states

Spinal Fusion and Decompression (for New Mexico Only)

Molecular Biomarkers for Prostate Cancer Risk Stratification - Medicare Advantage (Revised)

Prior Authorization Changes for Some Commercial and Government Program Members

Bariatric Surgery - Medicare Advantage (Revised)

Supplement 26-06: State of New Mexico Handicapping Labio-lingual Deviation (NM HLD) Index Report Form – MAD 908

Prior Authorization Changes for Some Commercial and Government Program Members

New Mexico Medicaid: Requirement to enroll with state delayed to October

Learn About Enhancements to Medicaid Utilization Management Process, Effective Sept. 18, 2026

Spinal Fusion Surgery - Medicare Advantage (Revised)

Benign Prostatic Hyperplasia Treatments - Medicare Advantage (Revised)

Ambulatory Cardiac Monitoring Devices - Medicare Advantage (Revised)

Neuroablative Techniques for Chronic Pain - Medicare Advantage (Revised)

Neuroablative Techniques for Chronic Pain - Medicare Advantage (Revised)

Genetic Testing for Hereditary Cancer - Medicare Advantage (Revised)

Breast Reconstruction - Medicare Advantage (Revised)

Breast Excision and Mastectomy - Medicare Advantage (Revised)

Benign Prostatic Hyperplasia Treatments - Medicare Advantage (Revised)

Prior Authorization Changes for Some Commercial and Government Program Members

New Claims Editing Rules To Be Implemented in July 2026

Two New Claims Editing Rules To Be Implemented in July 2026

Claim Editing Changes for Evaluation and Management Services for Commercial and Turquoise Care Members, Effective July 1, 2026